{
  "id": 2304310,
  "title": "Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline",
  "url": "https://urgent.news/2026/08/21/ipsen-completes-acquisition-of-kartos-therapeutics-strengthening-late",
  "topic": "business",
  "section": "Business",
  "published": "2026-08-21T05:00:29.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/ipsen-completes-acquisition-of-kartos-therapeutics-strengthening-late-stage-oncology-pipeline"
  },
  "original_language": "en",
  "account": null,
  "summary": "PARIS, FRANCE, 21 AUGUST 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor navtemadlin in Phase III clinical development in myelofibrosis. About navtemadlinNavtemadlin is an investigational oral MDM2 inhibitor being developed as an add-on therapy to…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}